SCOTTSDALE, Ariz., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Medicis’ United States patent application directed to the use of SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets in all five currently available dosage forms.
